Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b

The recent development of direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV) infection could lead to higher sustained virological response (SVR) rates, with shorter treatment durations and fewer adverse events compared with regimens that include interferon. However, a relatively s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanda, Tatsuo, Nirei, Kazushige, Matsumoto, Naoki, Higuchi, Teruhisa, Nakamura, Hitomi, Yamagami, Hiroaki, Matsuoka, Shunichi, Moriyama, Mitsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739919/
https://www.ncbi.nlm.nih.gov/pubmed/29290649
http://dx.doi.org/10.3748/wjg.v23.i46.8120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739919/
https://www.ncbi.nlm.nih.gov/pubmed/29290649
http://dx.doi.org/10.3748/wjg.v23.i46.8120

Ejemplares similares